Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination
Immune checkpoint therapy is one of the most promising immunotherapeutic methods that are likely able to give rise to durable treatment response for various cancer types. Despite much progress in the past decade, there are still critical open questions with particular regards to quantifying and pred...
Saved in:
| Main Authors: | Kamran Kaveh, Feng Fu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-10-01
|
| Series: | ImmunoInformatics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667119021000045 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
by: Vishnu Vijay Vijayan, et al.
Published: (2024-12-01) -
Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy
by: Sonja Cotra, et al.
Published: (2024-11-01) -
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer
by: Tatiana V. Kudling, et al.
Published: (2023-12-01) -
From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
by: Fang-Ju Huang, et al.
Published: (2025-12-01) -
Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer
by: Yan Wang, et al.
Published: (2024-12-01)